| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-668 | |
| Phytochemical name or plant extracts | Fraxetin (FXT) | |
| PMID | 31080186 | |
| Literature evidence | In conclusion, these findings suggest that FXT could be a promising lead compound to be used as a novel STAT3 inhibitor and potential antitumor agent for the treatment of NSCLC. | |
| IUPAC name | 7,8-dihydroxy-6-methoxychromen-2-one | |
| Phytochemicals’ class or type of plant extracts | Hydroxycoumarin | |
| Source of phytochemicals or plant Extracts | Fraxinus bungeana | |
| Geographical availability | China North-Central, China Southeast, Inner Mongolia, Manchuria | |
| Plant parts | NA | |
| Other cancers | Breast cancer, Lung cancer | |
| Target gene or protein | Fas, FasL, Bax, Bcl-2 | |
| Gene or Protein evidence | In conclusion, fraxetin can inhibit the proliferation of MCF-7 cells, induce apoptosis, upregulate Fas, FasL and Bax, and downregulate Bcl-2 to induce apoptosis. | |
| Target pathways | NA | |
| IC50 | FXT exhibited significant inhibitory effects on HCC827 and H1650 cells with IC50 values of 20.12 μM and 22.45 μM, respectively. | |
| Potency | NA | |
| Cell line/ mice model | MCF-7, HCC827, H1650, A549, H460, PC-9, H1975 | |
| Additional information | Fraxetin (FXT) is a potent plant-derived product and has been recognized as a promising anticancer agent for breast cancer and osteosarcoma. | |
| PubChem ID | 5273569 | |
| Additional PMIDs | 31080186 | |
| Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:608947-1 | |
| Safety | NA |